Abstract
Lung cancer is still a major cause of cancer deaths in spite of considerable efforts in its systemic therapy. Chemotherapy, along with local irradiation is frequently employed but as a palliative therapy. Inherent and acquired resistance in NSCLC and SCLC towards chemotherapeutic agents further makes chemotherapy an incommodious problem. The resistance mechanisms responsible for inherent DOX-resistance of NSCLC and acquired DOX-resistance in SCLC have been the subject of numerous investigations. This review will focus on the recent studies done for understanding the mechanism(s) of inherent and acquired resistance in NSCLC and SCLC and how these can be exploited for the future development of more effective novel biologic agents for the treatment of lung cancer.
Original language | English |
---|---|
Pages (from-to) | 1505-1511 |
Number of pages | 7 |
Journal | International journal of oncology |
Volume | 34 |
Issue number | 6 |
DOIs | |
State | Published - 2009 |
Keywords
- Cancer
- Doxorubicin
- Drug-resistance
- Glutathione conjugate transport
- PKCα
- RLIP76